drugset / Trial / NCT07360275

A Study of VCT220 in Participants With Hypertension and Obesity or Overweight

NCT07360275

Phase 2 Not yet recruiting 160 enrolled Vincentage Pharma Co., Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to explore the safety and efficacy of VCT220 for the treatment of hypertension in participants with obesity or overweight.

Timeline

Start
2026-03-01
Primary completion
2026-10-20
Completion
2026-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject VCT220 Small molecule 80 mg Oral
Subject VCT220 Small molecule 160 mg Oral

Indications